Harbin Pharmaceutical Group Co (SHSE:600664) Common Stock: ¥2,519 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600664 Harbin Pharmaceutical Group Co Ltd SHSE:600664
66 GF Score
Price ¥5.74
GF Value ¥3.51
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Harbin Pharmaceutical Group Co Common Stock?

Harbin Pharmaceutical Group Co SHSE:600664 +1.77% 66 Common Stock is ¥2,519 Mil as of Mar. 2026. GuruFocus rates SHSE:600664 with a GF Score™ of 66/100 and a GF Value™ of ¥3.51 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Harbin Pharmaceutical Group Co's quarterly common stock stayed the same from Sep. 2025 (¥2,519 Mil) to Dec. 2025 (¥2,519 Mil) and stayed the same from Dec. 2025 (¥2,519 Mil) to Mar. 2026 (¥2,519 Mil).

Harbin Pharmaceutical Group Co's annual common stock declined from Dec. 2023 (¥2,521 Mil) to Dec. 2024 (¥2,519 Mil) but then stayed the same from Dec. 2024 (¥2,519 Mil) to Dec. 2025 (¥2,519 Mil).

Harbin Pharmaceutical Group Co Common Stock Historical Data

* Premium members only.

The historical data trend for Harbin Pharmaceutical Group Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harbin Pharmaceutical Group Co Common Stock Chart

Harbin Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,518.38 2,525.88 2,521.28 2,518.51 2,518.51

Harbin Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,518.51 2,518.51 2,518.51 2,518.51 2,518.51
SHSE:600664
66GF Score
Harbin Pharmaceutical Group Co Ltd SHSE:600664
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harbin Pharmaceutical Group Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of ¥2,519 Mil mean?
Harbin Pharmaceutical Group Co (SHSE:600664) has a Common Stock of ¥2,519 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Harbin Pharmaceutical Group Co and its competitors.
Is Harbin Pharmaceutical Group Co's Common Stock too high?
Harbin Pharmaceutical Group Co's current Common Stock is ¥2,519 Mil. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's Common Stock compare to ZTS?
Harbin Pharmaceutical Group Co's Common Stock of ¥2,519 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Harbin Pharmaceutical Group Co and its competitors. Harbin Pharmaceutical Group Co's current Common Stock is ¥2,519 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.51, compared to a current price of ¥5.74 — trading 63.5% above its estimated fair value. The current Common Stock is ¥2,519 Mil. Harbin Pharmaceutical Group Co's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current Common Stock is ¥2,519 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?

Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be overvalued. The current stock price of ¥5.74 is trading 63.5% above its estimated GF Value™ of ¥3.51. GuruFocus considers Harbin Pharmaceutical Group Co to be Significantly Overvalued.

Key valuation signals for SHSE:600664:

  • Common Stock: ¥2,519 Mil
  • GF Value™: ¥3.51 vs. price of ¥5.74 (63.5% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harbin Pharmaceutical Group Co Business Description

Address Xi\'an Street West, People \'s Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
66GF Score

Get the complete analysis for SHSE:600664

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.74
Price
¥3.51
GF Value